EUVIMEDEUVIMED entdecken
Crossref

Epidemiological Patterns and Prevalence of HPV Genotypes in Iran: Implications for Prevention, Treatment, and Public Health Strategies

Nazanin Shabani, Hesamoddin Ahmadi Afzadi, Seyed Ehsan Alavian, Zahra Ziafati Kafi, Fatemeh Shalchi, Kimia Ghadimi, Fatemeh Gheidar, Bahram Zarmehri, Behzad Pourhossain, Maryam Fazeli

International Pharmacy Acta · 18.05.2025

DOI: 10.22037/ipa.v8i1.47719 ↗

Kurz gefasst

Fachartikel in der Zeitschrift International Pharmacy Acta, erschienen am 18.05.2025. Verfasst von Nazanin Shabani und 9 weiteren Autor:innen.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Human Papillomavirus (HPV), underlying cervical cancer, emerges as a critical risk factor and plays a significant role in the disease burden. In several countries across the Middle East, the absence of structured HPV screening programs and limited public awareness have made HPV a growing concern for public health due to its potential impact on women's health. Thus, this study aims to investigate the genotype-specific prevalence of HPV infections and analyze their distribution across different age groups to inform tailored preventive strategies. A cross-sectional study examining the distribution of HPV genotypes was conducted on persons who accessed laboratory facilities in Tehran from 2022 to 2024. PCR-based testing was performed on 4,167 samples submitted for HPV detection and genotyping. Information concerning the age and gender of the patients and the distribution of HPV based on the different genotypes was collected and sorted for statistical analysis. Among the 4,167 individuals referred for HPV testing, the overall positivity rate was 39.9% (1,662/4,167). The highest positivity rates were observed in the 26–30 (18.4%) and 31–35 (23.4%) age groups, with a declining trend in older age groups. Women represented 93.5% of the tested individuals, with a positivity rate of 38.1%, while the rate in men was 65.2%. The most frequent high-risk genotypes detected were HPV-31 (22.4%), HPV-51 (16.7%), and HPV-16 (15.8%). A weak negative correlation was observed between age and HPV positivity (r = -0.135, p < 0.001). The distribution of HPV genotypes observed in this referred population showed a predominance of high-risk types among those tested. These findings are not generalizable to the broader population due to the inherent selection bias, as participants sought HPV testing for clinical reasons. Nonetheless, the results highlight the importance of implementing structured screening and surveillance systems to understand better and manage the HPV burden in the country. As this study was based on individuals referred for HPV testing in selected areas of Tehran, the results reflect referral-based patterns and should not be interpreted as representative of nationwide HPV prevalence across Iran.

Schlagwörter

human papillomavirusHPV genotypesHPV prevalenceHPV16HPV51HPV 31high-risk HPVcervical cancerage distribution of HPV infectionHPV testing

Zitieren

APA

Shabani, N., Afzadi, H. A., Alavian, S. E., Kafi, Z. Z., Shalchi, F., Ghadimi, K., Gheidar, F., Zarmehri, B., Pourhossain, B., & Fazeli, M. (2025). Epidemiological Patterns and Prevalence of HPV Genotypes in Iran: Implications for Prevention, Treatment, and Public Health Strategies. International Pharmacy Acta. https://doi.org/10.22037/ipa.v8i1.47719

Vancouver

Shabani N, Afzadi HA, Alavian SE, Kafi ZZ, Shalchi F, Ghadimi K, et al. Epidemiological Patterns and Prevalence of HPV Genotypes in Iran: Implications for Prevention, Treatment, and Public Health Strategies. International Pharmacy Acta. 2025. doi:10.22037/ipa.v8i1.47719

BibTeX
@article{Shabani2025,
  author = {Shabani, Nazanin and Afzadi, Hesamoddin Ahmadi and Alavian, Seyed Ehsan and Kafi, Zahra Ziafati and Shalchi, Fatemeh and Ghadimi, Kimia and Gheidar, Fatemeh and Zarmehri, Bahram and Pourhossain, Behzad and Fazeli, Maryam},
  title = {Epidemiological Patterns and Prevalence of HPV Genotypes in Iran: Implications for Prevention, Treatment, and Public Health Strategies},
  journal = {International Pharmacy Acta},
  year = {2025},
  doi = {10.22037/ipa.v8i1.47719}
}
Kostenlos starten →